NCT03069937View on ClinicalTrials.gov

Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

March 3, 2021

Study Completion Date

December 11, 2024

Conditions
Metastatic Prostatic Adenocarcinoma
Interventions
DRUG

Docetaxel

The docetaxel dose is a 75mg/m2 intravenous (given through the vein) injection.

DRUG

Degarelix

Degarelix will be given as a subcutaneous (given under the skin) injection in the abdomen. The first dose will be a 240mg dose; all other doses will be 80 mg.

Trial Locations (1)

29425

Medical University of South Carolina, Charleston

Sponsors

Collaborators (1)

Ferring Pharmaceuticals
All Listed Sponsors
collaborator

Ferring Pharmaceuticals

INDUSTRY

lead

Medical University of South Carolina

OTHER

NCT03069937 - Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer. | Biotech Hunter | Biotech Hunter